Governing nonconventional genetic experimentation.

IF 2.4 2区 哲学 Q1 ETHICS Journal of Law and the Biosciences Pub Date : 2023-03-09 eCollection Date: 2023-01-01 DOI:10.1093/jlb/lsad003
Maxwell J Mehlman, Ronald A Conlon, Alex Pearlman
{"title":"Governing nonconventional genetic experimentation.","authors":"Maxwell J Mehlman, Ronald A Conlon, Alex Pearlman","doi":"10.1093/jlb/lsad003","DOIUrl":null,"url":null,"abstract":"<p><p>A large and highly heterogeneous group of individuals conducts genetic and genomic research outside of traditional corporate and academic settings. They can be an important source of innovation, but their activities largely take place beyond the purview of existing regulatory systems for promoting safe and ethical practices. Historically the gene-targeting technology available for non-traditional genomic research has been limited, and therefore these activities have attracted little regulatory attention. New technologies such as CRISPR/Cas9, however, give nonconventional experimenters more extensive gene editing abilities at an unprecedented level of accessibility. The affordability and accessibility of these powerful technologies are raising questions about whether the current largely laissez-faire governance approach is adequate. This article recommends steps to enhance self-governance, including establishing umbrella organizations to represent community interests, creating a community IRB modelled on the DIYBio Ask a Safety Expert Service, and adopting an ethical obligation to report rogue experiments.</p>","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"10 1","pages":"lsad003"},"PeriodicalIF":2.4000,"publicationDate":"2023-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997442/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Law and the Biosciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jlb/lsad003","RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ETHICS","Score":null,"Total":0}
引用次数: 0

Abstract

A large and highly heterogeneous group of individuals conducts genetic and genomic research outside of traditional corporate and academic settings. They can be an important source of innovation, but their activities largely take place beyond the purview of existing regulatory systems for promoting safe and ethical practices. Historically the gene-targeting technology available for non-traditional genomic research has been limited, and therefore these activities have attracted little regulatory attention. New technologies such as CRISPR/Cas9, however, give nonconventional experimenters more extensive gene editing abilities at an unprecedented level of accessibility. The affordability and accessibility of these powerful technologies are raising questions about whether the current largely laissez-faire governance approach is adequate. This article recommends steps to enhance self-governance, including establishing umbrella organizations to represent community interests, creating a community IRB modelled on the DIYBio Ask a Safety Expert Service, and adopting an ethical obligation to report rogue experiments.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
管理非常规基因实验。
在传统的企业和学术环境之外,有一个庞大且高度多元化的群体在进行基因和基因组研究。他们可以成为创新的重要源泉,但他们的活动在很大程度上超出了促进安全和道德实践的现有监管体系的范围。从历史上看,非传统基因组研究可用的基因靶向技术有限,因此这些活动很少引起监管机构的关注。然而,CRISPR/Cas9 等新技术为非传统实验者提供了更广泛的基因编辑能力,其可获得性达到了前所未有的水平。这些强大技术的可负担性和可获得性正在引发人们的疑问:目前基本上放任自流的管理方法是否足够?本文建议采取一些措施来加强自我管理,包括建立代表社区利益的伞式组织,以 DIYBio "询问安全专家 "服务为模式建立社区 IRB,以及承担道德义务报告不法实验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Law and the Biosciences
Journal of Law and the Biosciences Medicine-Medicine (miscellaneous)
CiteScore
7.40
自引率
5.90%
发文量
35
审稿时长
13 weeks
期刊介绍: The Journal of Law and the Biosciences (JLB) is the first fully Open Access peer-reviewed legal journal focused on the advances at the intersection of law and the biosciences. A co-venture between Duke University, Harvard University Law School, and Stanford University, and published by Oxford University Press, this open access, online, and interdisciplinary academic journal publishes cutting-edge scholarship in this important new field. The Journal contains original and response articles, essays, and commentaries on a wide range of topics, including bioethics, neuroethics, genetics, reproductive technologies, stem cells, enhancement, patent law, and food and drug regulation. JLB is published as one volume with three issues per year with new articles posted online on an ongoing basis.
期刊最新文献
Is the current regulatory framework for direct-to-consumer microbiome-based tests sufficient to protect consumers from medical, economic, and dignitary harms? Heritable human genome editing and the politics of law: the South African case study. The Indian regulatory framework and the surge of unproven stem cell therapies-a call for diagnosis. The future of AI regulation in drug development: a comparative analysis. Ensuring vaccine access through local production: the need for a harmonized and sustainable approach.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1